Here’s the biotech recap for the week of Nov. 3 and a look ahead to this week’s action. The Nasdaq Biotechnology Index (NBI) lost 1.2% last week, closing at 726 on Friday, while the Amex Biotechnology Index (BTK) lost 2.7% to close at 656 on Friday
Source: www.thestreet.com
Amylin, Orient-Express, PFG, Sun: U.S. Equity Movers (Correct) - Bloomberg
Nov. 4 (Bloomberg) — The following companies are having unusual price changes in U.S. trading today. Stock symbols are in parentheses, and share prices are as of 12:15 p.m. in New York. Amylin Pharmaceuticals Inc. (AMLN US) retreated 21 percent to
Source: www.bloomberg.com
UPDATE 1-Genzyme, Osiris to develop stem cell products - Reuters
Nov 4 (Reuters) - Genzyme Corp (GENZ.O: Quote , Profile , Research , Stock Buzz ) said it would co-develop and market two adult stem cell products of Osiris Therapeutics (OSIR.O: Quote , Profile , Research , Stock Buzz ) that are being tested for
Source: www.reuters.com
Refer to a friend - PR Inside
Rodman & Renshaw Annual Global Investment Conference - Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and
Source: www.pr-inside.com
Osiris Therapeutics to Present at 20th Annual Piper Jaffray Health - StreetInsider.com
COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ: OSIR ), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas
Source: www.streetinsider.com